Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment ...

Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

its pan HER2 inhibitor for a form of lung cancer, according to South Korea's Hanmi Pharma, which originally developed the drug. Hanmi reported the FDA's rejection of the marketing application ...

Relay Therapeutics gains capital via licensing, reduces costs, and advances its promising PI3K-alpha inhibitor. See why RLAY ...

EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

Treatment decisions post-CDK4/6 inhibitor progression depend on tumor-specific mutations, with options like Orserdu and Piqray available. Recent advancements and new drug approvals underscore the ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

Puma Biotechnology offers runway stability but lacks clear growth drivers amid drug headwinds and pipeline gaps. Find out why ...

SUZHOU, China, March 18, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...